Lv5
1230 积分 2025-03-02 加入
Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer
6天前
已完结
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
6天前
已关闭
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
6天前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 edition)]
6天前
已完结
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
7天前
已完结
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
7天前
已完结
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
7天前
已完结
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
7天前
已完结
Upregulation of Trop-2 quantitatively stimulates human cancer growth
7天前
已完结
The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
7天前
已完结
皖公网安备34019202002308
